Hollister Biosciences Inc. (CSE: HOLL) (OTC: HSTRF) (FRANKFURT: HOB) (the
Company ,
Hollister Cannabis Co. or
Hollister ) a diversified cannabis branding company with products in over 280 dispensaries throughout California, and over 90 dispensaries throughout Arizona, is pleased to provide an update on its Q4, 2020 performance.
Q4 2020 Update
st, 2020 and ending December 31
st, 2020, Hollister reports that it generated record quarterly revenue of CDN$14.93 million and CDN$2.53 million in EBITDA from its product line of pre-rolls, concentrates, distillates, solvent-free bubble hash, pre-packaged flower, tinctures and vape products. The Company cautions that revenue and EBITDA figures have not yet been audited and are based on reports prepared by management.
Further Research into Psilocybin Opens New Doors for Treatment
FinancialBuzz.com News Commentary
Share this article
Share this article
NEW YORK, Jan. 7, 2021 /PRNewswire/ Among the popular fields of study for biotech companies in recent years are gene editing, tissue engineering and regeneration, nanobiotechnology and others. In addition, new segments under the biotech umbrella are constantly being developed. For example, the medical cannabis segment has rapidly emerged in recent years, and the continuously growing acceptance of psychedelic drugs is further evidence. The perceptions about psychedelics and their possible uses have also started to shift from a potentially dangerous party drug to an approachable medicinal product. For example, earlier in 2019, the U.S. Food and Drug Administration (FDA) approved Spravato (esketamine) a nasal spray, in conjunction with an oral antidepressant, for the treatment of depression in adults who have tried other antidepressant medicines b
Investorideas com - Investor Ideas Potcasts #510, Cannabis News and Stocks on the Move (TSX: WEED) (NASDAQ: CGC) (TSX: RIV) (CSE: HOLL) (TSX: VFF) investorideas.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investorideas.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
Company ,
Hollister Cannabis Co. or
Hollister ) a diversified cannabis branding company with products in over 280 dispensaries throughout California, and over 80 dispensaries throughout Arizona, is pleased to announce the launch of its 2nd fulfillment depot for its direct-to-consumer cannabis delivery platform, Dreamy Delivery (
Dreamy or the
Platform ).
The Company soft launched Dreamy Delivery to friends and family in the San Francisco Bay Area of Northern California, to ensure a seamless customer experience in early Q4 of 2020. The Company has expanded the Platform, with Dreamy now successfully delivering to legal cannabis consumers in the San Francisco Bay Area of Northern California and now Sacramento, California. The Company hopes to launch Dreamy in the Central Coast of California by early Q1 of 2021 with the ultimate goal of delivering Cannabis statewide.
Push for Alternative Therapies Prods Researchers Towards Psilocybin
FinancialBuzz.com News Commentary
NEW YORK, Dec. 15, 2020 /PRNewswire/ The psychedelics market is currently navigating a similar legal situation to the one the cannabis market found itself in for many years. Psychedelics are not legal for recreational use in Canada or the United States, yet medical research on the efficiency of such products may help reduce some of the stigma around them. In fact, some major developments have already begun to change the landscape for the better in this market. For example, earlier in 2019, the state of Colorado became the first state to decriminalize Magic Mushrooms (mushrooms containing psilocybin), taking the substance on a similar path to legalization as that of cannabis. Then, in November 2019, the FDA awarded the second Breakthrough Therapy designation to non-profit Usona Institute, which is studying the effects of psilocybin as an anti-depressant. Currently, despite the obs